Dr. Alan Zajarias and the team at the Valvular Heart Disease Center have been invited to join the Edwards Triscend 2 pivotal trial, testing the safety and effectiveness of the Evoque valve device in patients with tricuspid regurgitation.
The Evoque tricuspid valve replacement system is designed to use an implant to replace the native tricuspid valve without open-heart surgery. The trial includes patients with severe or greater tricuspid regurgitation (TR).
The Valvular Heart Disease Center is continuing to expand an impressive portfolio of clinical trials, with ongoing trials for tavr, tavr for AI with Jenna Valve, TEER with mitraclip, TEER with Pascal for FMR, TMVR with intrepid (transseptal), and tricuspid repair with Pascal and tric valve (superior and inferior caval stent valves). This innovative work continues to put Washington University School of Medicine on the cutting edge of cardiovascular medicine.